Rachid Baz, MD
Patients with relapsed/refractory multiple myeloma have a plethora of options based on positive findings from the ARROW, ELOQUENT-3, and OPTIMISMM trials, calling attention to the importance of dosing, scheduling, and choice of regimen, explained Rachid Baz, MD.
“There is no real algorithm on how to manage relapsed/refractory multiple myeloma,” said Baz. “However, those studies add to the therapeutic armamentarium that we have and to the options that patients have when they face their disease.”
... to read the full story